Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Lapadula, Giuseppe ^a   Chatenoud, Liliane ^b   Gori, Andrea ^a   Castelli, Francesco ^c   Di Giambenedetto, Simona ^d   Fabbiani, Massimiliano ^d   Maggiolo, Franco ^e   Focà, Emanuele ^c   Ladisa, Nicoletta ^f   Sighinolfi, Laura ^g,m   Di Pietro, Massimo ^h   Pan, Angelo ⁱ   Torti, Carlo ^c,j,k   Carosi, G ^c   Quiros, E ^c   Nasta, P ^c   Paraninfo, G ^c   Cauda, R ^d   Colafigli, M ^d   Scalzini, A ^l   Castelnuovo, F ^l   El Hamad, I ^l   Mazzotta, F ^h   Locaputo, S ^h   Pierotti, P ^h   Marino, N ^h   Ble C ^h   Vichi, F ^h   Angarano, G ⁿ   Ladisa, N ⁿ   Monno, L ⁿ   Maggi, P ⁿ   Costarelli, S ⁱ   Puoti, M ^o   Viale, P ^p   Colangeli, V ^p   Borderi, M ^p   more..

^a SAN GERARDO HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f Ospedale Consorziale Policlinico   (Italy)

^g Ospedale Sant'Anna di Cona   (Italy)

^h SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

ⁱ CREMONA HOSPITAL   (Italy)

^j UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^k Policlinico Mater Domini   (Italy)

^l SPEDALI CIVILI   (Italy)

^m S ANNA HOSPITAL   (Italy)

ⁿ POLICLINICO   (Italy)

^o OSPEDALE NIGUARDA CA GRANDA   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEATH; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIXED INFECTION; NON ACQUIRED IMMUNE DEFICIENCY SYNDROME DEFINING EVENT; PHYSICAL DISEASE; RISK FACTOR; TREATMENT RESPONSE; ACQUIRED IMMUNODEFICIENCY SYNDROME; CARDIOVASCULAR DISEASES; COINFECTION; COMORBIDITY; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; LIVER DISEASES; MIDDLE AGED; NEOPLASMS; PROCEDURES; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COINFECTION; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; VIRAL LOAD;

EID: 84932627615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124741     Document Type: Article

References (40)

1. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van LJ, et al. (2000) Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 160: 1123-1132. PMID: 10789605
2. Marimoutou C, Chene G, Mercie P, Neau D, Farbos S, Morlat P, et al. (2001) Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr 27: 161-167. PMID: 11404538
3. Dronda F, Moreno S, Moreno A, Casado JL, Perez-Elias MJ, Antela A (2002) Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis 35: 1005-1009. PMID: 12355389
4. Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, et al. (2010) A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 55: 451-459. PMID: 21105259
5. van Lelyveld SF, Gras L, Kesselring A, Zhang S, De WF, Wensing AM, et al. (2012) Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 26: 465-474. doi: 10.1097/QAD.0b013e32834f32f8 PMID: 22112603
6. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, et al. (2005) Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 40: 288-293. PMID: 16249702
7. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, et al. (2008) Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47: 553-558. doi: 10.1097/QAI.0b013e31816856c5 PMID: 18285713
8. Grabar S, Le M, V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401-410. PMID: 10975957
9. Zoufaly A, an der HM, Kollan C, Bogner JR, Fatkenheuer G, Wasmuth JC, et al. (2011) Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 203: 364-371. doi: 10.1093/jinfdis/jiq055 PMID: 21208929
10. Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Roge B, et al. (2010) Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis 10: 318. doi: 10.1186/1471-2334-10-318 PMID: 21044307
11. Gutierrez F, Padilla S, Masia M, Iribarren JA, Moreno S, Viciana P, et al. (2008) Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 6: 100-107. PMID: 18336257
12. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al. (2014) Long-term Mortality in HIVPositive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin Infect Dis.
13. Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, et al. (2013) Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS 27: 769-779. doi: 10.1097/QAD.0b013e32835cb747 PMID: 23719349
14. Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, et al. (2007) Predictors of AIDS-defining events among advanced naive patients after HAART. HIV Clin Trials 8: 112-120. PMID: 17621458
15. Italian MASTER cohort web-site. [Italian] http://www.mastercohort.it Last accessed: April 21st 2014.
16. Sighinolfi L, Torti C, Zeni C, Ghinelli F, Suter F, Maggiolo F, et al. (2008) Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. Infection 36: 244-249. doi: 10.1007/s15010-007-7227-0 PMID: 18454340
17. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254. PMID: 16908915
18. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41: 1-19. PMID: 1480128
19. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, et al. (2009) Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48: 1138-1151. doi: 10.1086/597468 PMID: 19275498
20. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. (2011) Late presentation of HIV infection: a consensus definition. HIV Med 12: 61-64. doi: 10.1111/j.1468-1293.2010.00857.x PMID: 20561080
21. Ndiaye B, Salleron J, Vincent A, Bataille P, Bonnevie F, Choisy P, et al. (2011) Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis 11: 11. doi: 10.1186/1471-2334-11-11 PMID: 21226905
22. Agwu AL, Neptune A, Voss C, Yehia B, Rutstein R (2014) CD4 counts of nonperinatally HIV-infected youth and young adults presenting for HIV care between 2002 and 2010. JAMA Pediatr 168: 381-383. doi: 10.1001/jamapediatrics.2013.4531 PMID: 24493261
23. Mocroft A, Lundgren JD, Sabin ML, Monforte A, Brockmeyer N, Casabona J, et al. (2013) Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 10: e1001510. doi: 10.1371/journal.pmed.1001510 PMID: 24137103
24. Wilson KD, Dray-Spira R, Aubriere C, Hamelin C, Spire B, Lert F (2014) Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group-results from the ANRSVESPA2 Study, France. AIDS Care 1-11. doi: 10.1080/09540121.2014.946384 PMID: 25117749
25. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, et al. (2009) Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 52: 357-363. doi: 10.1097/QAI.0b013e3181b62933 PMID: 19668084
26. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543. PMID: 12721933
27. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, et al. (2006) Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20: 1727-1736. PMID: 16931937
28. Massanella M, Negredo E, Perez-Alvarez N, Puig J, Ruiz-Hernandez R, Bofill M, et al. (2010) CD4 Tcell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24: 959-968. doi: 10.1097/QAD.0b013e328337b957 PMID: 20177358
29. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. (2011) Impact of CD8+ Tcell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 25: 2123-2131. doi: 10.1097/QAD.0b013e32834c4ac1 PMID: 21881481
30. Lau B, Gange SJ, Moore RD (2007) Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 44: 179-187. PMID: 17075385
31. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. (2010) Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 55: 262-270. doi: 10.1097/QAI.0b013e3181e9be6b PMID: 20700060
32. Neuhaus J, Angus B, Kowalska JD, La RA, Sampson J, Wentworth D, et al. (2010) Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 24: 697-706. doi: 10.1097/QAD.0b013e3283365356 PMID: 20177360
33. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. (2005) Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 41: 361-372. PMID: 16007534
34. Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, et al. (2009) Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 50: 457-463. PMID: 19360931
35. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB (2010) Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 24: 1857-1865. doi: 10.1097/QAD.0b013e32833adbb5 PMID: 20479633
36. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC (2009) Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49: 225-232. doi: 10.1086/599371 PMID: 19508169
37. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, et al. (2012) Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26: 1917-1926. PMID: 22781222
38. Webster DP, Klenerman P, Dusheiko GM (2015) Hepatitis C. Lancet [ePub ahed of print]. pii: S0140-6736(14)62401-6. doi: 10.1016/S0140-6736(14)62401-6 PMID: 25687730
39. Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, et al. (2014) Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One 9: e87160. doi: 10.1371/journal.pone.0087160 PMID: 24498036
40. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679-686. PMID: 12957089